Monday, 9 May 2016

NICE considers new disease modifying treatment for MS

Source MS Society:
The European Medicines Agency (EMA) has recommended daclizumab, known as Zinbryta, be licensed to treat people with relapsing forms of MS.

The National Institute for Health and Care Excellence (NICE) is now deciding whether to make this treatment available on the NHS in England and Wales.  Read on.